The ras-oncogene-encoded p21 protein, a G-protein, that is normally activated by binding GTP in place of GDP, is present in all eukaryotic cells and is known to be critical in the regulation of the cell cycle becomes oncogenic when amino acids are substituted at critical positions such as Val-for-Gly 12 and Leu-for-Gin 61. The oncogenic but not the normal, protein, causes cell transformation when microinjected into NIH- 3T3 cells and maturation of Xenopus laevis oocytes. To determine the specific activating conformational changes, conformational analysis, using a combination of molecular dynamics based on the computer program DISCOVER and an electric dipole moment-Monte Carol method (EDMC) based on the computer program ECEPP (Empirical Conformational Energies of Peptides Program), will be performed on the normal p21-GDP complex, the activated p21-GTP complex, and a series of non-oncogenic and oncogenic mutant proteins. Comparison of the average structures for the non- oncogenic and oncogenic proteins will highlight regions of major structural differences between them. Peptides from these regions will be synthesized and tested for their abilities to block oncogenic p21 protein-induced oocyte maturation. Thus, far, six different p21 segments have been so identified, and peptides from three of these regions (35-47, 96-110, and 115-126) have been found to block oncogenic p21-induced oocyte maturation. To identify the protein targets of p21 and these peptides intracellularly, photoaffinity-labeled Val 12-p21 photoaffinity- labeled active peptides will be introduced into cells to enable them to label their targets covalently. These proteins will be identified by immunoprecipitation, SDS-PAGE, and microsequencing. A protein of MW 43 kda has been isolated, using this technique, that may be MAP-2 kinase or MAP kinase kinase (MKK) and will be microsequenced and blotted with antibodies to these proteins. The inhibitory peptides and other anti-ras agents completely block oncogenic p21-induced oocyte maturation but not maturation induced by insulin which activates normal cellular ras. Also, protein kinase C has been found to be an essential target of oncogenic but not normal p21. These findings suggest that a major divergence in signal pathways occurs between oncogenic and activated normal ras- promoted p34-cyclin activation of this enzyme, inhibitors of the cyclin system will be tested to determine if they selectivity block insulin but not Val 12-p21-induced oocyte maturation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042500-10
Application #
2090763
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1988-09-30
Project End
1997-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
10
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Narrows Institute for Biomedical Research Inc
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
11209
Sarafraz-Yazdi, Ehsan; Bowne, Wilbur B; Adler, Victor et al. (2010) Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A 107:1918-23
Deng, Lili; Boujdir, Mohamed; Tremontano, Anthony et al. (2009) A peptide from a ras effector-domain blocks ras-dependent cardiac hypertrophy in myocytes. Ann Clin Lab Sci 39:351-60
Bowne, Wilbur B; Sookraj, Kelley A; Vishnevetsky, Michael et al. (2008) The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol 15:3588-600
Bowne, Wilbur B; Michl, Josef; Bluth, Martin H et al. (2007) Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer. Cancer Ther 5B:331-344
Qu, Yongxia; Adler, Victor; Chu, Tearina et al. (2006) Two dual specificity kinases are preferentially induced by wild-type rather than by oncogenic RAS-P21 in Xenopus oocytes. Front Biosci 11:2420-7
Michl, Josef; Scharf, Bruce; Schmidt, Anna et al. (2006) PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer 119:1577-85
Chie, Lyndon; Chung, Denise; Pincus, Matthew R (2005) Specificity of inhibition of ras-p21 signal transduction by peptides from GTPase activating protein (GAP) and the son-of sevenless (SOS) ras-specific guanine nucleotide exchange protein. Protein J 24:253-8
Smith, Steven; Hyde, Mark; Pincus, Matthew R (2005) Comparison of the predicted structures of loops in the ras-SOS protein bound to a single ras-p21 protein with the crystallographically determined structures in SOS bound to two ras-p21 proteins. Protein J 24:391-8
Adler, Victor; Qu, Yongxia; Smith, Steven J et al. (2005) Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Biochemistry 44:10784-95
Rosal, Ramon; Brandt-Rauf, Paul; Pincus, Matthew R et al. (2005) The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev 57:653-60

Showing the most recent 10 out of 98 publications